Malignant pleural mesothelioma: when is radiation therapy indicated?

References

• Travis WB, Müller-Hermelink HK, Harris CC. World Health Organization classification of tumours. Tumours of the lung, pleura, thymus and heart. IARC, Lyon, France (2004).
   Google Scholar
• Robinson BW, Musk AW, Lake RA. Malignant mesothelioma. Lancet366, 397–408 (2005).
   PubMed Web of Science ®Google Scholar
• Testa JR, Pass HI, Carbone M. Benign and malignant mesothelioma. Principles and Practice of Oncology (6th Editon). Lippincott Williams & Wilkins, PA, USA, 1937 (2001).
   Google Scholar
• Rusch VW, Rosenzweig K, Venkatraman E et al. A Phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J. Thorac. Cardiovasc. Surg.122, 788–795 (2001).
   PubMed Web of Science ®Google Scholar
• Boutin C, Rey F, Gouvernet J et al. Thoracoscopy in pleural malignant mesothelioma: a prospective study of 188 consecutive patients. Cancer72, 394–404 (1993).
   PubMed Web of Science ®Google Scholar
• Rusch VM; The International Mesothelioma Interest Group (IMIG). A proposed new international TNM staging system for malignant pleural mesothelioma. Chest108, 1122–1128 (1995).
   PubMed Web of Science ®Google Scholar
• Francart J, Vaes E, Henrard S et al. A prognostic index for progression free survival in malignant mesothelioma with application to the design of Phase II trial: an analysis of 10 combined EORTC trials. Eur. J. Cancer45, 2304–2311 (2009).
   PubMedGoogle Scholar
• Eibel R, Tuengerthal S, Schoenberg SO. The role of new imaging techniques in diagnosis and staging of malignant pleural mesothelioma. Curr. Opin. Oncol.15, 131–138 (2003).
   PubMedGoogle Scholar
• Wang ZJ, Reddy GP, Gotway MB et al. Malignant pleural mesothelioma: evaluation with CT, MR imaging, and PET. Radiographics24, 105–119 (2004).
   PubMed Web of Science ®Google Scholar
• Plathow C, Staab A, Schmaehl A et al. Computed tomography, positron emission tomography, positron emission tomography/computed tomography, and magnetic resonance imaging for staging of limited pleural mesothelioma: initial results. Invest. Radiol.43(10), 737–744 (2008).
   PubMedGoogle Scholar
• Vogelzang NJ, Rusthoven JJ, Symanowski J et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J. Clin. Oncol.21, 2636–2644 (2003).
   PubMed Web of Science ®Google Scholar
• Van Meerbeeck JP, Manegold C, Gaafar R et al. A randomized Phase III study of cisplatine with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the EORTC lung cancer group and NCIC. J. Clin. Oncol.23, 6881–6889 (2005).
   PubMed Web of Science ®Google Scholar
• Gordon W, Antman KH, Greenberger JS et al. Radiation therapy in the management of patients with mesothelioma. Int. J. Radiat. Oncol. Biol. Phys.8, 19–25 (1982).
   PubMed Web of Science ®Google Scholar
• Bissett D, Macbeth FR, Cram I. The role of palliative radiotherapy in malignant mesothelioma. Clin. Oncol. (R. Coll. Radiol.)3, 315–317 (1991).
   PubMedGoogle Scholar
• Ball DL, Cruickshank DG. The treatment of malignant mesothelioma of the pleura: review of a 5-year experience, with special reference to radiotherapy. Am. J. Clin. Oncol.13, 4–9 (1990).
   PubMed Web of Science ®Google Scholar
• De Graaf-Strukowska L, Van der Zee J, Van Putten W et al. Factors influencing the outcome of radiotherapy in malignant mesothelioma of the pleura – a single-institution experience with 189 patients. Int. J. Radiat. Oncol. Biol. Phys.43(3), 511–516 (1999).
   PubMed Web of Science ®Google Scholar
• Van der Zee J, van de Pol M, Praag JO. Letter to the editor. Radiother. Oncol.70, 99 (2004).
   PubMedGoogle Scholar
• Boutin C, Rey F, Viallat JR. Prevention of malignant seeding after invasive diagnostic procedures in patients with pleural mesothelioma. A randomized trial of local radiotherapy. Chest108, 754–758 (1995).
   PubMed Web of Science ®Google Scholar
• Bydder S, Phillips M, Joseph DJ et al. A randomised trial of single-dose radiotherapy to prevent procedure tract metastasis by malignant mesothelioma. Br. J. Cancer91, 9–10 (2004).
   PubMed Web of Science ®Google Scholar
• O’Rourke N, Garcia JC, Paul J et al. A randomised controlled trial of intervention site radiotherapy in malignant pleural mesothelioma. Radiother. Oncol.84, 18–22 (2007).
   PubMed Web of Science ®Google Scholar
• Muirhead R, O’Rourke N. Drain site radiotherapy in malignant pleural mesothelioma: a wasted resource. Eur. Respir. J.30, 1021–1022 (2007).
   PubMedGoogle Scholar
• Ung YC, Yu E, Falkson C et al. The role of radiation therapy in malignant pleural mesothelioma: a systematic review. Radiother. Oncol.80, 3–8 (2006).
   Google Scholar
• De Ruysscher D, Slotman B. Treatment of intervention sites of malignant pleural mesothelioma with radiotherapy: a Dutch–Belgian survey. Radiother. Oncol.68, 299–302 (2003).
   PubMedGoogle Scholar
• Senan S. Indications and limitations of radiotherapy in malignant pleural mesothelioma, Curr. Opin. Oncol.15, 144–147 (2003).
   PubMed Web of Science ®Google Scholar
• Hilaris BS, Nori D, Kwong E et al. Pleurectomy and intraoperative brachytherapy and postoperative radiation in the treatment of malignant pleural mesothelioma. Int. J. Radiat. Oncol. Biol. Phys.10, 325–331 (1984).
   PubMedGoogle Scholar
• Law MR, Gregor A, Hodson ME et al. Malignant mesothelioma of the pleura: a study of 52 treated and 64 untreated patients. Thorax39, 255–259 (1984).
   PubMed Web of Science ®Google Scholar
• Alberts AS, Falkson G, Goedhals L et al. Malignant pleural mesothelioma: a disease unaffected by current therapeutic maneuvers. J. Clin. Oncol.6, 527–535 (1988).
   PubMed Web of Science ®Google Scholar
• Sugarbaker DJ, Garcia JP, Richards WG et al. Extrapleural pneumonectomy in the multimodality therapy of malignant pleural mesothelioma. Results in 120 consecutive patients. Ann. Surg.224, 288–294 (1996).
   PubMedGoogle Scholar
• Gupta V, Mychalczak B, Krug L et al. Hemithoracic radiation therapy after pleurectomy/decortication for malignant pleural mesothelioma. Int. J. Radiat. Oncol. Biol. Phys.63, 1045–1052 (2005).
   PubMed Web of Science ®Google Scholar
• Kutcher GJ, Kestler C, Greenblat D et al. Technique for external beam treatment for mesothelioma. Int. J. Radiat. Oncol. Biol. Phys.13, 1747–1752 (1987).
   PubMed Web of Science ®Google Scholar
• Achatzy R, Beba W, Ritschler R et al. The diagnosis, therapy and prognosis of diffuse malignant mesothelioma. Eur. J. Cardiothorac. Surg.3, 445–448 (1989).
   PubMedGoogle Scholar
• Soysal O, Karaoglanoglu N, Demircan S et al. Pleurectomy/decortication for palliation in malignant pleural mesothelioma: results of surgery. Eur. J. Cardiothorac. Surg.11, 210–213 (1997).
   PubMedGoogle Scholar
• Ahamed A, Stevens CW, Smythe WR et al. Intensity-modulated radiation therapy: a novel approach to the management of malignant pleural mesothelioma. Int. J. Radiat. Oncol. Biol. Phys.55, 768–775 (2003).
   PubMedGoogle Scholar
• Yajnik S, Rosenzweig KE, Mychalczak B et al. Hemithoracic radiation after extrapleural pneumonectomy for malignant pleural mesothelioma. Int. J. Radiat. Oncol. Biol. Phys.56, 1319–1326 (2003).
   PubMed Web of Science ®Google Scholar
• Forster KM, Smythe WR, Starkschall G et al. Intensity modulated radiotherapy following extrapleural pneumonectomy for the treatment of malignant mesothelioma: clinical implementation. Int. J. Radiat. Oncol. Biol. Phys.55, 606–616 (2003).
   PubMed Web of Science ®Google Scholar
• Van Meerbeeck JP, Surmont VF, Scherpereel A et al. Malignant pleural mesothelioma: the standard of care and challenges for future management. Crit. Rev. Oncol. Hematol. DOI: 10.1016/j.critrevonc.2010.04.004 (2010) (Epub ahead of print).
   PubMedGoogle Scholar
• Rice DC, Stevens CW, Correa AM et al. Outcomes after extrapleural pneumonectomy and intensity-modulated radiation therapy for malignant pleural mesothelioma. Ann. Thorac. Surg.84, 1685–1693 (2007).
   PubMed Web of Science ®Google Scholar
• Miles EF, Larrier NA, Kelsey CR et al. Intensity-modulated radiotherapy for resected mesothelioma: the Duke experience. Int. J. Radiat. Oncol. Biol. Phys.71, 1143–1150 (2008).
   PubMed Web of Science ®Google Scholar
• Rice DC, Smythe WR, Stevens C et al. Dose-dependent pulmonary toxicity after postoperative intensity-modulated radiotherapy for malignant pleural mesothelioma. Int. J. Radiat. Oncol. Biol. Phys.69, 350–347 (2007).
   PubMed Web of Science ®Google Scholar
• Rosenzweig K, Krug L, Laser B et al. Feasibility of pleural intensity-modulated radiation therapy (IMRT) for malignant mesothelioma. J. Thor. Oncol.4(9), S774 (2009).
   Google Scholar
• Krayenbuehl J, Hartmann M, Lomax AJ et al. Proton therapy for malignant pleural mesothelioma after extrapleural pleuropneumonectomy. Int. J. Radiat. Oncol. Biol. Phys.77, 942–949 (2010).
   PubMedGoogle Scholar
• Sugarbaker DJ, Flores RM, Jaklitsch MT et al. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J. Thorac. Cardiovasc. Surg.117, 54–63 (1999).
   PubMed Web of Science ®Google Scholar
• Flores RM, Pass HI, Seshan VE et al. Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients. J. Thorac. Cardiovasc. Surg.135, 620–626 (2008).
   PubMed Web of Science ®Google Scholar
• Weder W, Stahel RA, Bernhard J et al.; Swiss Group for Clinical Cancer Research (SAKK). Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. Ann. Oncol.18, 1196–1202 (2007).
   PubMed Web of Science ®Google Scholar
• Krug LM, Pass HI, Rusch VW et al. Multicenter Phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma. J. Clin. Oncol.27, 3007–3013 (2009).
   PubMed Web of Science ®Google Scholar
• de Perrot M, Feld R, Choy BC et al. Trimodality therapy with induction chemotherapy followed by extrapleural pneumonectomy and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J. Clin. Oncol.27, 1413–1418 (2009).
   PubMed Web of Science ®Google Scholar
• Van Schil PE, Baas P, Gaafar R et al. Phase II trial of trimodality therapy for malignant pleural mesothelioma (EORTC 08031). Eur. Respir. J.36(6), 1362–1369 (2010).
   PubMed Web of Science ®Google Scholar
• Hillerdal G, Sorensen JB, Sundström S et al. Treatment of malignant pleural mesothelioma with carboplatin, liposomized doxorubicin, and gemcitabine: a Phase II study. J. Thorac. Oncol.3, 1325–1331 (2008).
   PubMedGoogle Scholar
• Treasure T, Waller D, Tan C et al. The Mesothelioma and Radical Surgery randomized controlled trial: the MARS feasibility study. J. Thorac. Oncol.4, 1254–1258 (2009).
   PubMedGoogle Scholar
• Scherpereel A, Astoul P, Baas P et al. Guidelines of the ERS/ESTS for management of malignant pleural mesothelioma. Eur. Resp. J.35, 479–495 (2010).
   PubMed Web of Science ®Google Scholar